RevieweNeuro2024

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.

Michelle Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.